The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP
Open accessAbstract
Down syndrome, caused by trisomy of chromosome 21, is the single most common risk factor for early-onset Alzheimer's disease. Worldwide approximately 6 million people have Down syndrome, and all these individuals will develop the hallmark amyloid plaques and neurofibrillary tangles of Alzheimer's disease by the age of 40 and the vast majority will go on to develop dementia. Triplication of APP, a gene on chromosome 21, is sufficient to cause early-onset Alzheimer's disease in the absence of Down syndrome. However, whether triplication of other chromosome 21 genes influences disease pathogenesis in the context of Down syndrome is unclear. Here we show, in a mouse model, that triplication of chromosome 21 genes other than APP increases amyloid-β aggregation, deposition of amyloid-β plaques and worsens associated cognitive deficits. This indicates that triplication of chromosome 21 genes other than APP is likely to have an important role to play in Alzheimer's disease pathogenesis in individuals who have Down syndrome. We go on to show that the effect of trisomy of chromosome 21 on amyloid-β aggregation correlates with an unexpected shift in soluble amyloid-β 40/42 ratio. This alteration in amyloid-β isoform ratio occurs independently of a change in the carboxypeptidase activity of the γ-secretase complex, which cleaves the peptide from APP, or the rate of extracellular clearance of amyloid-β. These new mechanistic insights into the role of triplication of genes on chromosome 21, other than APP, in the development of Alzheimer's disease in individuals who have Down syndrome may have implications for the treatment of this common cause of neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Trisomy of chromosome 21 promotes the intracellular and extracellular deposition of amyloid-β. (A and B) Intracellular amyloid-β deposition (82E1) was increased by trisomy in hippocampal CA3 pyramidal neurons in 4.5–6.5-month-old mice [ANOVA trisomy-tgAPP interaction F(1,31) = 5.125, P = 0.031] [Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.012; wild-type (WT) (black circles) n = 10, trisomic (blue squares) n = 10, tgAPP (red triangles) n = 10, trisomic;tgAPP (purple inverted triangles) n = 10]. (C) A trend for increased hippocampal Tris-soluble multimeric amyloid-β (82E1-82E1 ELISA) normalized to the sum of amyloid-β38, amyloid-β40 and amyloid-β42 in trisomic;tgAPP was observed [trisomy F(1,24) = 3.928, P = 0.059; tgAPP n = 8, trisomic;tgAPP n = 11)]. (D–I) Amyloid-β deposition (6F/3D) in the hippocampus was quantified at (D–F) 6 and (G–I) 16 months of age. Trisomy increases (E and H) the number of plaques [tgAPP–trisomy interaction F(1,77) = 6.744, P = 0.011, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.008, 16 months P = 0.003] and (F and I) the area covered by amyloid-β [tgAPP–trisomy interaction F(1,85) = 4.005, P = 0.049, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.097, 16 months P = 0.037] (6 months wild-type n = 8, trisomic = 8, tgAPP n = 15, trisomic;tgAPP n = 13; 16 months wild-type n = 16, trisomic = 9, tgAPP n = 13, trisomic;tgAPP n = 11). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were studied and sex was included as a factor in the ANOVA. Scale bar in A = 50 µm; D and G = 500 µm. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/c172967425154239b3614fe878be331a/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-1.jpg)
![Figure 2 Trisomy of chromosome 21 promotes the aggregation of amyloid-β. (A–F) Cortical proteins from 16-month-old mice were fractionated and 5 M guanidine hydrochloride soluble amyloid-β quantified by (A–E) Meso Scale Discovery Assay or (F) mass spectrometry. (A and B) No effect of trisomy on amyloid-β38 [tgAPP-trisomy interaction F(1,28) = 0.385, P = 0.540] or amyloid-β40 [tgAPP-trisomy interaction F(1,28) = 0.962, P = 0.355] was observed, (C) but significantly more amyloid-β42 was detected in trisomic;tgAPP mice [tgAPP-trisomy interaction F(1,28) = 5.573, P = 0.025] (Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.005, wild-type n = 6, trisomic = 6, tgAPP n = 13, trisomic;tgAPP n = 11). (D and E) No change in the amyloid-β38/42 ratio [trisomy F(1,19) = 0.072, P = 0.792] or amyloid-β40/42 ratio [trisomy F(1,19) = 0.047, P = 0.831] was observed. (F) The relative abundance of different forms of amyloid-β peptides was not altered by trisomy of chromosome 21 (tgAPP n = 12, trisomic;tgAPP n = 10). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a factor in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/7de3168d568a462da08e5c9eb594be35/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-2.jpg)
![Figure 3 Trisomy of chromosome 21 exacerbates APP/amyloid-β-associated cognitive deficits. (A and B) Exposure to a novel open field was used as a test of activity and habituation (6 months, wild-type n = 28, trisomic n = 28, TgAPP n = 20, trisomic;tgAPP n = 18). (A) Overall activity: ANOVA of distance travelled revealed a main effect of tgAPP [F(1,78) = 26.250, P < 0.001], trisomy [F(1,78) = 9.246, P = 0.003], and a tgAPP-trisomy interaction [F(1,78) = 7.818, P = 0.007] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P = 0.008). (B) The total distance moved declined with exposure time (1-min time bins) ANOVA: main effect of time bin [F(29,2262) = 12.399 P < 0.001]; an interaction of time bin × trisomy [ANOVA F(29,2262) = 1.789 P = 0.006], time bin × tgAPP [F(29,2262) = 1.560 P = 0.029] and time bin × trisomy;tgAPP [F(29,2262) = 1.983, P < 0.001] was observed by ANOVA. (C and D) A Y-maze spatial novelty preference task (1-min delay) was used as a test of activity and memory. (Cohort B 2–3 months and Cohort A 6–7 months, the effect of genotype was similar in both cohorts so data were combined for analysis, wild-type n = 45, trisomic n = 43, TgAPP n = 36, trisomic;tgAPP n = 26). (C) ANOVA of the number of arm entries (test phase), revealed a main effect of trisomy [F(1,89) = 50.360, P < 0.001], tgAPP [F(1,89) = 47.001, P < 0.001], and a tgAPP–trisomy interaction [F(1,89) = 31.720, P < 0.001] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P < 0.001). (D) A preference ratio of 0.5 indicates chance performance (black dotted line). ANOVA of novelty preference revealed a main effect of trisomy [F(1,89) = 10.144 P = 0.002], tgAPP [F(1,89) = 9.312 P = 0.003] and a tgAPP–trisomy interaction [F(1,89) = 5.736, P = 0.019] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001 and trisomic P = 0.010). Performance of tgAPP–trisomic mice was above chance (one-sample t-test t = 3.287 P < 0.001). (E) A discrete-trial, longitudinal spontaneous alternation task in a T-maze was used as a test of memory, 50% alternation represents chance performance (black dotted line) (2–3 months wild-type n = 29, trisomic n = 30, TgAPP n = 21, trisomic;tgAPP n = 17, 6–7 months wild-type n = 28, trisomic n = 29, TgAPP n = 20, trisomic;tgAPP n = 17, 15–16 months wld-type n = 27, trisomic n = 26, TgAPP n = 27, trisomic;tgAPP n = 11). ANOVA of alternation showed a main effect of trisomy [F(1,67) = 7.084 P = 0.010], and an interaction of tgAPP–trisomy [F(1,67) = 4.706, P = 0.034] (Bonferroni pairwise comparison trisomic;tgAPP with wild-type P = 0.032). Performance of tgAPP-trisomic mice was above chance (one-sample t-test, 2–3 months t = 5.884 P < 0.001, 6–7 months t = 5.378 P < 0.001, 15–16 months t = 6.495 P < 0.001). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/0728074d79e94df39d2ed6dbe5f83fa1/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-3.jpg)
![Figure 4 Trisomy of chromosome 21 genes other than APP does not increase APP abundance nor alter β-CTF/α-CTF ratio. (A, B and D) Full-length APP (FL-APP), APP β-CTF and APP α-CTF were measured in cortex (wild-type n = 17, trisomic n = 16, tgAPP n = 24, trisomic;tgAPP n = 19) and hippocampus (wild-type n = 11, trisomic n = 12, tgAPP n = 24, trisomic;tgAPP n = 17) at 3 months of age. (A) Full-length APP was higher in tgAPP and trisomic;tgAPP compared with wild-type or trisomic mice [cortex F(1,68) = 87.667, P < 0.001, hippocampus F(1,56) = 94.301, P < 0.001]. Trisomy did not alter full-length APP [trisomy–tgAPP interaction, cortex F(1,68) = 0.483, P = 0.489, hippocampus F(1,56) = 2.457, P = 0.123]. (B and C) In male mice, APP-CTF/full-length APP ratio was altered (cortex tgAPP n = 17, trisomic;tgAPP n = 11, hippocampus tgAPP n = 14, trisomic;tgAPP n = 8) β-CTF/full-length APP (t-test cortex P = 0.005, hippocampus P = 0.0217) and α-CTF/full-length APP (t-test cortex P = 0.005 hippocampus P < 0.001). (D) Trisomy did not alter the β-CTF/α-CTF ratio in the cortex [trisomy F(1,37) = 0.065, P = 0.799] or hippocampus [trisomy F(1,37) = 1.082, P = 0.305]. (B) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. WT = wild-type.](https://figures.cochat.ai/paper-figures/3778828581a64b7596da739983aabf31/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-4.jpg)
![Figure 5 Trisomy of chromosome 21 genes other than APP does not alter α-/β-secretase activity. Trisomy did not alter (A) soluble β-APP abundance [trisomy F(1,24) = 0.790, P = 0.383, trisomy-tgAPP interaction F(1,24) = 0.773, P = 0.388, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14], (B and C) cortical BACE1 abundance [trisomy F(1,24) = 0.002, P = 0.963; trisomy–tgAPP interaction F(1,24) = 0.071, P = 0.792, wild-type n = 6, trisomic n = 6, TgAPP n = 9, trisomic;tgAPP n = 7], (D) BACE1 β-secretase activity [trisomy F(1,13) = 0.006, P = 0.941; trisomy–tgAPP interaction F(1,13) = 0.001 P = 0.971, wild-type n = 6, trisomic n = 6, TgAPP n = 4, trisomic;tgAPP n = 5], or (E) soluble α-APP abundance [trisomy F(1,27) = 0.041, P = 0.841; trisomy–tgAPP interaction F(1,27) = 0.002, P = 0.969, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14]. (C) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM. Both sexes were analysed and sex was included as a factor in the ANOVA. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/b3aef28883bf4eaa91210dbb2249b115/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-5.jpg)

![Figure 7 Trisomy of chromosome 21 modulates amyloid-β ratios in vivo independently of modulation of γ-secretase activity. (A–C) Tris-soluble amyloid-β38, amyloid-β40 and amyloid-β42 were measured by Meso Scale Discovery 6E10 Aβ Triplex assay in 2-month-old hippocampus (wild-type n = 24, trisomic n = 22, TgAPP n = 25 and trisomic;tgAPP n = 27). (A) Trisomy decreased amyloid-β38 [trisomy F(1,4) = 15.403, P = 0.017] and amyloid-β40 [trisomy F(1,11) = 6.359, P = 0.028], but amyloid-β42 was not changed [trisomy F(1,11) = 2.978, P = 0.112], (B) resulting in an alteration in the amyloid-β38/42 ratio [trisomy F(1,4) = 14.553, P = 0.019] and (C) the amyloid-β40/42 ratio [trisomy F(1,10) = 95.694, P < 0.001]. (D) Hippocampal amyloid-β40/42 ratio negatively correlates with the relative abundance of aggregated amyloid-β (multimeric 82E1-82E1 amyloid-β ELISA) (linear correlation, R2 = 0.5485, P = 0.0003, tgAPP n = 8, trisomic;tgAPP n = 11). Trisomy did not alter the carboxypeptidase activity of the γ-secretase complex, as measured by (E and G) amyloid-β38/42 and (F and H) amyloid-β40/42 ratios produced in vitro by the complex isolated from cortex from (E and F) the Tc1 trisomic mouse [trisomy amyloid-β38/42 F(1,11) = 4.88, P = 0.499; amyloid-β42/40 F(1,11) = 0.799, P = 0.395, wild-type = 9, trisomic = 9] and (G and H) people with Down syndrome and Alzheimer’s disease (AD-DS) (n = 6) compared with age- and sex-matched individuals who did not have Down syndrome or dementia (control n = 6) [trisomy amyloid-β38/42 F(1,5) = 0.102, P = 0.763; amyloid-β42/40 F(1,5) = 0.187, P = 0.684]. (A–F) Data are represented as mean ± SEM, (G and H) individual cases plotted, horizontal line indicates mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and females were studied and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.](https://figures.cochat.ai/paper-figures/ab4297bc73604e059748d7a5a4125e9e/trisomy-of-human-chromosome-21-enhances-amyloid-deposition-independently-of-an-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, it has been shown in preclinical models of DS-AD that triplication of HSA21 genes modulates Aβ aggregation and APP transgene-associated mortality independently of an extra copy of APP.17,18”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have indicated that an additional copy of HSA21 genes can alter APP biology, including Aβ deposition in other APP transgenic models.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence in preclinical models demonstrates that genes other than APP being in three copies modify aspects of DSAD, such as cognition and amyloid-β load [1, 50, 70]”
From Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease (2025) · cites this paper as [70]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In AD brain, markers of ER stress are elevated and correlate with progression of this disorder53,54,58.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [58]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In response to abnormal elevated levels of misfolded proteins and/or free Ca2+ in the ER lumen, the unfolded protein response (UPR) is engaged53,54,58.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“J20-tgAPP mice overexpress a human APP transgene with Alzheimer’s disease mutations and accumulates amyl- oid-b within the brain from (cid:5) 4–5 months of age (Mucke et al. , 2000).”
Preparation of PCR-Quality Mouse Genomic DNA with Hot Sodium Hydroxide and Tris (HotSHOT)
Truett, G. E., Heeger, P., Mynatt, R. L., Truett, A. A., Walker, J. A., & Warman, M. L. (2000) · BioTechniques · doi:10.2144/00291bm09 · Cited by 1,738 · cited 1×
“DNA was extracted from tail tip or ear biopsy by the Hot Shot method (Truett et al. , 2000).”
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249 · cited 1×
“(Rovelet-Lecrux et al., 2006; Sleegers et al., 2006) making it likely that three copies of APP are important in the development of Down syndrome–Alzheimer’s disease.”
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 2×
“In vivo microdialysis In vivo microdialysis was used to assess brain interstitial fluid (interstitial fluid) amyloid-b40 half-life in awake mice as previously described (Castellano et al., 2011).”
MethodInfluentialSelf-citationTrafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 1×
“The first site of amyloid-b accumulation in people with Down syndrome is within the cell (Gouras et al., 2000; Gyure et al., 2001; Mori et al., 2002; Hirayama et al., 2003) in the endo- lysosomal system (Cataldo et al., 2000, 2004).”
BackgroundA mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 1×
“Ts65Dn or Dp(10)1Yey;Dp(16)1Yey;Dp(17)1Yey triple trisomic mice] do not form amyloid-b plaques even in elderly mice (26 months) (Reeves et al., 1995; Yu et al., 2010).”
T-maze alternation in the rodent
Deacon, R. M. J., & Rawlins, J. N. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.2 · Cited by 897 · cited 1×
“A T-shaped maze made of wood painted dark grey with 30 (cid:2) 10 (cid:2) 29 cm arms, with a central partition extending 7 cm into the start arm from the back of the maze, was used to assess spontaneous alternation as previously described (Deacon and Rawlins, 2006).”
The neurobiological basis of spontaneous alternation
Lalonde, R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00041-0 · Cited by 838 · cited 1×
“We note that the performance of wild-type mice declined with age in this task, as has been previously reported (Lalonde, 2002).”
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776 · cited 1×
“The first site of amyloid-b accumulation in people with Down syndrome is within the cell (Gouras et al., 2000; Gyure et al., 2001; Mori et al., 2002; Hirayama et al., 2003) in the endo- lysosomal system (Cataldo et al., 2000, 2004).”
Background
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
Iulita, M. F., Garzón Chavez, D., Klitgaard Christensen, M., Valle Tamayo, N., Plana-Ripoll, O., Rasmussen, S. A., Roqué Figuls, M., Alcolea, D., Videla, L., Barroeta, I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12910 · Cited by 195
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
Hithersay, R., Startin, C. M., Hamburg, S., Mok, K. Y., Hardy, J., Fisher, E. M. C., Tybulewicz, V. L. J., Nizetic, D., & Strydom, A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3616 · Cited by 176
Self-citation
Metadata
- Authors
- Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., Chávez-Gutiérrez, L., Cleverley, K., Noy, S., Sheppard, O., Collins, T., Powell, C., Sarell, C. J., Rickman, M., Choong, X., Tosh, J. L., Siganporia, C., Whittaker, H. T., Stewart, F., Szaruga, M., London Down syndrome consortium, Murphy, M. P., Blennow, K., de Strooper, B., Zetterberg, H., Bannerman, D., Holtzman, D. M., Tybulewicz, V. L. J., Fisher, E. M. C., The LonDownS Consortium, Strydom, A., Fisher, E., Nizetic, D., Hardy, J., Tybulewicz, V., & Karmiloff-Smith, A.
- Affiliations
- King's College London (GB)
- UCL Queen Square Institute of Neurology (GB)
- University of Oxford (GB)
- Washington University in St. Louis (US)
- University of Gothenburg (SE)
- University of Kentucky (US)
- VIB-KU Leuven Center for Brain and Disease Research, VIB-Leuven 3000, Center for Human Genetics, Universitaire Ziekenhuizen and LIND, KU Leuven, Leuven, Belgium
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG UK
- MRC Prion Unit (GB)
- UK Dementia Research Institute (GB)
- The LonDownS Consortium, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, London, SE5 8AF, UK
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-06-26
- Volume
- 141
- Issue
- 8
- Pages
- 2457-2474
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6061702
- OpenAlex
- W2810011474
- Cited by
- 133
- References
- 68
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 22 · 2020: 20 · 2019: 16 · 2018: 4
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by)
- Lirias (submittedVersion, other-oa)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- Wellcome Trust Strategic Award (098330/Z/12/Z)
- London Down Syndrome (LonDownS) Consortium
- Wellcome Trust Joint Senior Investigators Award
- Medical Research Council (U117527252, G0601056, FC001194)
- Alzheimer’s Research UK
- Alzheimer’s Society
- Epilepsy Research UK
- Torsten Söderberg Foundation at the Royal Swedish Academy of Sciences
- Francis Crick Institute
- Cancer Research UK (FC001194)
- Wellcome Trust (FC001194)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Down syndrome, amyloid-beta deposition, amyloid plaques, Alzheimer's disease, amyloid-beta aggregation, cognitive impairment, gamma-secretase, APP, mouse model
- MeSH terms
- Alzheimer Disease, Animals, Brain, Disease Models, Animal, Down Syndrome, Female, Humans, Male, Mice, Inbred C57BL, Trisomy, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP. https://app.cochat.ai/papers/10.1093/brain/awy159
- The paper
- Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., Chávez-Gutiérrez, L., Cleverley, K., Noy, S., Sheppard, O., Collins, T., Powell, C., Sarell, C. J., Rickman, M., Choong, X., Tosh, J. L., Siganporia, C., Whittaker, H. T., Stewart, F., . . . Karmiloff-Smith, A. (2018). Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP. Brain. https://doi.org/10.1093/brain/awy159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.